CytoDyn faces DOJ, SEC subpoenas after promoting failed Covid-19 drug
The little, PR-happy drug company publicly called out by the FDA is now getting attention from both the SEC and the Department of Justice.
CytoDyn, a one-time penny stock that has gained both money and notoriety for aggressively pushing an old HIV drug as a treatment for Covid-19, disclosed in a regulatory filing Friday the SEC and DOJ have separately subpoenaed the company and “certain of its executives” as part of investigations into the company’s promotion and marketing practices.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.